Zou Yidi, Luo Yong, Zhang Jun, Xia Ningshao, Tan Guowei, Huang Chenghao
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University.
Department of Neurosurgery, First Affiliated Hospital of Xiamen University, Xiamen, China.
Medicine (Baltimore). 2019 Aug;98(35):e16817. doi: 10.1097/MD.0000000000016817.
Accumulating evidence in the last decade has pointed to the effectiveness of oncolytic virus in the treatment of a variety of cancer types in preclinical or clinical studies, showing high potency and low toxicity compared to conventional treatments. To track this research trend and highlight future directions, we conducted a bibliometric analysis of oncolytic virus research to date.
Relevant studies were obtained from the Web of Science Core Collection between January 2000 and December 2018. Data were collected in terms of the number of publications, country, journal of publication, journal scope, author, and keywords or topics. Analysis and visual representation of the data were performed with CiteSpace V.
The trend in publications related to oncolytic virus showed a dramatic increase, from 10 publications in 2000 to 199 publications in 2018. The United States clearly dominates this field (981 publications, 52.770%), followed by Canada (244, 13.125%) and China (205, 11.027%). The top 15 academic journals account for over one third of the total publications on oncolytic virus research (724, 38.95%). Most of the related papers were published in journals with a focus on biology, medicine, immunology, medicine, molecular biology, and clinical perspectives, as represented by the dual-map overlay. The most highly cited papers were published in journals in the fields of nursing, molecular biology, general biology, genetics, health, and medicine. Over 1300 institutions have focused their attention on oncolytic virus research to date, and cooperation among mainstream institutions is common.
The global field of oncolytic virus research has expanded at a rapid pace from 2000 to 2018. There is no doubt that North America currently has the most powerful impact on the field with respect to both productivity and contribution. However, European and some East Asian institutions are also prominent in this field. Overall, this bibliometric study identifies the top 4 hotspots in oncolytic virus research: T-cells, vaccinia virus, dendritic cells, and apoptosis. Thus, further research focuses on these topics may be more helpful to promote the clinical translation of this treatment strategy to bring a benefit to cancer patients in the near future.
过去十年间,越来越多的证据表明溶瘤病毒在临床前或临床研究中对多种癌症类型的治疗具有有效性,与传统治疗方法相比,显示出高效能和低毒性。为追踪这一研究趋势并突出未来方向,我们对迄今为止的溶瘤病毒研究进行了文献计量分析。
从2000年1月至2018年12月的科学引文索引核心合集获取相关研究。收集的数据包括出版物数量、国家、出版期刊、期刊范围、作者以及关键词或主题。使用CiteSpace V对数据进行分析和可视化呈现。
与溶瘤病毒相关的出版物数量呈显著增长趋势,从2000年的10篇增至2018年的199篇。美国在该领域占据明显主导地位(981篇出版物,占52.770%),其次是加拿大(244篇,占13.125%)和中国(205篇,占11.027%)。前15种学术期刊占溶瘤病毒研究总出版物的三分之一以上(724篇,占38.95%)。如双图叠加所示,大多数相关论文发表在专注于生物学、医学、免疫学、分子生物学和临床视角的期刊上。被引用次数最多的论文发表在护理、分子生物学、普通生物学、遗传学、健康和医学领域的期刊上。迄今为止,超过1300个机构关注溶瘤病毒研究,主流机构之间的合作很常见。
从2000年到2018年,全球溶瘤病毒研究领域迅速扩展。毫无疑问,目前北美在该领域的生产力和贡献方面影响最大。然而,欧洲和一些东亚机构在该领域也很突出。总体而言,这项文献计量研究确定了溶瘤病毒研究的前4个热点:T细胞、痘苗病毒、树突状细胞和细胞凋亡。因此,未来聚焦于这些主题的进一步研究可能更有助于推动这种治疗策略的临床转化,在不久的将来为癌症患者带来益处。